<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638180</url>
  </required_header>
  <id_info>
    <org_study_id>BUS-P5-703</org_study_id>
    <nct_id>NCT03638180</nct_id>
  </id_info>
  <brief_title>BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect</brief_title>
  <official_title>A Double-Blind, Placebo Controlled, Randomized, Adaptive, First-in-Human Study to Assess, Safety, Tolerability, Pharmacokinetics and Food Effect of Single and Multiple Doses of BLU-5937 Administered Orally in Healthy Male and Female</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellus Health Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellus Health Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human study that will investigate the safety, tolerability and
      pharmacokinetics of ascending single and multiple doses of BLU-5937 using a double blind,
      placebo controlled, randomized, adaptive, single center study design. The influence of food
      on the pharmacokinetics of BLU-5037 will also be investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BLU-5937 is a selective P2X3 receptor antagonist being developed for the treatment of chronic
      cough. This Phase 1 study will investigate the safety, tolerability and pharmacokinetics of
      ascending single and multiple doses of BLU-5937 administered orally to healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Actual">October 25, 2018</completion_date>
  <primary_completion_date type="Actual">October 25, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>up to 48 hours after the last dose</time_frame>
    <description>Number and severity of TEAEs collected from dosing until follow up 48 hours after last dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>up to 48 hours after the last dose</time_frame>
    <description>To assess Cmax of single and multiple ascending oral doses of BLU-5937</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>up to 48 hours after the last dose</time_frame>
    <description>To assess AUC of single and multiple ascending oral doses of BLU-5937</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) under fed conditions</measure>
    <time_frame>up to 48 hours after the last dose</time_frame>
    <description>To assess Cmax of a single oral dose of BLU-5937 under fed conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) under fed conditions</measure>
    <time_frame>up to 48 hours after the last dose</time_frame>
    <description>To assess AUC of a single oral dose of BLU-5937 under fed conditions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Cough</condition>
  <arm_group>
    <arm_group_label>Single Ascending Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses, 6 dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending doses, 3 dose levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLU-5937</intervention_name>
    <description>BLU-5937 oral tablet</description>
    <arm_group_label>Multiple Ascending Doses</arm_group_label>
    <arm_group_label>Single Ascending Doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to BLU-5937</description>
    <arm_group_label>Multiple Ascending Doses</arm_group_label>
    <arm_group_label>Single Ascending Doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male and/or female (non-childbearing potential or, for women of
             childbearing potential, using 2 forms of acceptable birth control or agreed to abide
             by true abstinence),

          -  Age: 18 to 55 years (inclusive).

          -  Body mass index (BMI) : ≥18.5 and ≤30 kg/m².

          -  Non or ex smoker.

        Exclusion Criteria:

          -  Any findings from the medical examination (including medical history, physical
             examination, vital signs, laboratory tests and ECG) outside from normal and deemed by
             the investigator to be clinically significant.

          -  Use of any prescription drugs (with the exception of hormone replacement therapy) in
             the 28 days prior to the first study drug administration, that in the opinion of the
             investigator would put into question the status of the volunteer as healthy.

          -  Volunteers who took an Investigational Product in the 28 days prior to the first study
             drug administration.

          -  Volunteers who donated 50 mL or more of blood in the 28 days prior to the first study
             drug administration.

          -  Donation of 500 mL or more of blood in the 56 days prior to the first study drug
             administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alta Sciences Algorithme Pharma</name>
      <address>
        <city>Mount-Royal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>November 8, 2018</last_update_submitted>
  <last_update_submitted_qc>November 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

